Insight, China's Pharmaceutical Industry

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990), a China-based biopharmaceutical company, announced it has received...

Company

WuXi AppTec Files Federal Lawsuit Against U.S. Department of Defense Over Erroneous Inclusion on Chinese Military Companies List

Fineline Cube Jun 12, 2026

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359), a leading China-based contract research organization (CRO),...

Company Deals

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

Fineline Cube Jun 12, 2026

HJ Science Co., Ltd., (HKG: 6132) a China-based clinical-stage biotechnology company, announced its proposed initial...

Company Drug

LongBio Pharma’s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial

Fineline Cube Jun 12, 2026

LongBio Pharma (HKG: 1779), a China-based biomacromolecule drug developer, announced that the Phase III clinical...

Company Deals

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

Fineline Cube Jun 12, 2026

Cascade Pharmaceuticals, Inc., a Shanghai-based sino-foreign joint venture biotechnology company, has secured RMB 318 million...

Company Drug

Novartis’ Del-Brax Meets Primary Endpoints in FSHD Biomarker Study – Potential First Disease-Modifying Therapy for Rare Muscular Dystrophy

Fineline Cube Jun 12, 2026

Novartis AG (NYSE: NVS) announced that the biomarker cohort of the FORTITUDE Phase I/II clinical...

Company Deals

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Fineline Cube Jun 11, 2026

QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., announced a strategic AI-powered collaboration with an...

Company Drug

Novartis Secures Fourth China Approval for Tafinlar-Mekinist Combo in BRAF V600E-Mutated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Fineline Cube Jun 11, 2026

Novartis AG (NYSE: NVS) announced that China’s National Medical Products Administration (NMPA) has granted approval...

Company Drug

Yipinhong Pharmacy Receives NMPA Clearance for APH03571 Dual-Mechanism Therapy in FLT3-Mutated Relapsed/Refractory AML

Fineline Cube Jun 11, 2026

Yipinhong Pharmacy Co., Ltd. (SHE: 300723) announced it has received Investigational New Drug (IND) clearance...

Company Drug

CSPC Pharmaceutical’s Phase III Trial of Anbenitamab-Docetaxel Combination Meets Primary Endpoint in First-Line HER2-Positive Advanced Breast Cancer

Fineline Cube Jun 11, 2026

CSPC Pharmaceutical Group (HKG: 1093) announced that its Phase III clinical trial evaluating Ennituo (anbenitamab)...

Others

Harbour BioMed’s IND for HBM7004 Bispecific Antibody Accepted by NMPA for Advanced Solid Tumors Following U.S. Clearance

Fineline Cube Jun 11, 2026

Harbour BioMed (HKG: 2142) announced that China’s National Medical Products Administration (NMPA) has accepted its...

Company Deals

QingSong Health and Basel Medical Forge Three-Year Strategic Alliance to Deploy AI-Driven Healthcare Solutions Across Southeast Asia

Fineline Cube Jun 11, 2026

QingSong Health (HKG: 2661) announced a three-year strategic cooperation memorandum of understanding (MoU) with Singapore-headquartered...

Company Drug

Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases

Fineline Cube Jun 11, 2026

Imviva Biotech announced it has received Investigational New Drug (IND) clearance from the U.S. Food...

Company Drug

Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis

Fineline Cube Jun 11, 2026

Akeso Biopharma (HKG: 9926) announced it has received marketing approval from China’s National Medical Products...

Company Drug

Hansoh Pharmaceutical’s NDA for HS-10568 Calcium-Sensing Receptor Modulator Accepted by China’s NMPA for Secondary Hyperparathyroidism in Dialysis Patients

Fineline Cube Jun 11, 2026

Hansoh Pharmaceutical Group Co., Ltd. (HKG: 3692) announced that China’s National Medical Products Administration (NMPA)...

Others

Orionis Biosciences Secures $1.44 Billion Novartis Partnership for Molecular Glue Drug Discovery Using AI-Powered Allo-Glue Platform

Fineline Cube Jun 11, 2026

Orionis Biosciences announced a multi-year strategic collaboration with global pharmaceutical leader Novartis AG (NYSE: NVS)...

Company Drug

Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&J’s Stelara, Expanding Access Across Multiple Autoimmune Indications

Fineline Cube Jun 11, 2026

Bio-Thera Solutions Ltd. (SHA: 688177) announced it has received marketing approval from Singapore’s Health Sciences...

Company Drug Policy / Regulatory

PKU Hi-Tech Huatai Pharmaceuticals Blacklisted from China’s Volume-Based Procurement Following Quality Compliance Failures

Fineline Cube Jun 11, 2026

PKU Hi-Tech Huatai Pharmaceuticals Co., Ltd. has been blacklisted from China’s national volume-based procurement (VBP)...

Company Drug

Sanofi Halts Phase 3 MOBILIZE Trial for Riliprubart in Refractory CIDP Patients Following Interim Analysis

Fineline Cube Jun 11, 2026

Sanofi (NASDAQ: SNY) announced the discontinuation of its MOBILIZE phase 3 clinical trial evaluating riliprubart...

Company Drug

NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy

Fineline Cube Jun 10, 2026

NeuroGen Pharma announced it has received marketing approval from China’s National Medical Products Administration (NMPA)...

Insight, China's Pharmaceutical Industry

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

WuXi AppTec Files Federal Lawsuit Against U.S. Department of Defense Over Erroneous Inclusion on Chinese Military Companies List

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

LongBio Pharma’s Anti-IgE Antibody LP-003 Meets Primary Endpoint in Phase III Seasonal Allergic Rhinitis Trial

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

Novartis’ Del-Brax Meets Primary Endpoints in FSHD Biomarker Study – Potential First Disease-Modifying Therapy for Rare Muscular Dystrophy

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Novartis Secures Fourth China Approval for Tafinlar-Mekinist Combo in BRAF V600E-Mutated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Yipinhong Pharmacy Receives NMPA Clearance for APH03571 Dual-Mechanism Therapy in FLT3-Mutated Relapsed/Refractory AML

CSPC Pharmaceutical’s Phase III Trial of Anbenitamab-Docetaxel Combination Meets Primary Endpoint in First-Line HER2-Positive Advanced Breast Cancer

Harbour BioMed’s IND for HBM7004 Bispecific Antibody Accepted by NMPA for Advanced Solid Tumors Following U.S. Clearance

QingSong Health and Basel Medical Forge Three-Year Strategic Alliance to Deploy AI-Driven Healthcare Solutions Across Southeast Asia

Imviva Biotech Receives FDA Clearance for Phase 1b Basket Trial of CTA313 Allogeneic CAR-T Therapy in B Cell-Mediated Autoimmune Diseases

Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis

Hansoh Pharmaceutical’s NDA for HS-10568 Calcium-Sensing Receptor Modulator Accepted by China’s NMPA for Secondary Hyperparathyroidism in Dialysis Patients

Orionis Biosciences Secures $1.44 Billion Novartis Partnership for Molecular Glue Drug Discovery Using AI-Powered Allo-Glue Platform

Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&J’s Stelara, Expanding Access Across Multiple Autoimmune Indications

PKU Hi-Tech Huatai Pharmaceuticals Blacklisted from China’s Volume-Based Procurement Following Quality Compliance Failures

Sanofi Halts Phase 3 MOBILIZE Trial for Riliprubart in Refractory CIDP Patients Following Interim Analysis

NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy

You Missed

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis